Sarepta Therapeutics buy tamam
Start price
09.01.18
/
50%
€48.59
Target price
04.11.21
€153.34
Performance (%)
57.44%
End price
05.11.21
€76.50
Summary
This prediction ended on 05.11.21 with a price of €76.50. With a performance of 57.44% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Sarepta Therapeutics | -1.874% | -1.874% | 38.831% | 130.969% |
iShares Core DAX® | -3.935% | -2.628% | 10.013% | 11.951% |
iShares Nasdaq 100 | -3.608% | -9.283% | 20.668% | 35.711% |
iShares Nikkei 225® | -4.513% | -6.951% | 5.241% | 2.602% |
iShares S&P 500 | -2.607% | -4.402% | 20.177% | 37.820% |
Comments by tamam for this prediction
In the thread Sarepta Therapeutics diskutieren
Sarepta continues to be a core buy in biotech
In today´s investor update management guided for fourth quarter revenue of $57.3 million and full year 2018 Exondys 51 revenue in the range of $295 million to $305 million (roughly double that of 2017).
tamam stimmt am 09.01.2018 der Outperform-Einschätzung der institutionellen Analysten zu.
In the thread Trading Sarepta Therapeutics
Die von tamam gewählte maximale Laufzeit wurde überschritten